| Autor: |
Mannelli F; SOD Ematologia, Università di Firenze, AOU Careggi, Firenze, Italy; Centro Ricerca e Innovazione Malattie Mieloproliferative (CRIMM), AOU Careggi, Firenze. francesco.mannelli@unifi.it., Piccini M; SOD Ematologia, Università di Firenze, AOU Careggi, Firenze., Bencini S; Centro Diagnostico di Citofluorimetria e Immunoterapia, AOU Careggi, Firenze., Gianfaldoni G; SOD Ematologia, Università di Firenze, AOU Careggi, Firenze., Peruzzi B; Centro Diagnostico di Citofluorimetria e Immunoterapia, AOU Careggi, Firenze., Caporale R; Centro Diagnostico di Citofluorimetria e Immunoterapia, AOU Careggi, Firenze., Scappini B; SOD Ematologia, Università di Firenze, AOU Careggi, Firenze., Fasano L; SOD Ematologia, Università di Firenze, AOU Careggi, Firenze., Quinti E; SOD Ematologia, Università di Firenze, AOU Careggi, Firenze., Ciolli G; SOD Ematologia, Università di Firenze, AOU Careggi, Firenze., Pasquini A; SOD Ematologia, Università di Firenze, AOU Careggi, Firenze., Crupi F; SOD Ematologia, Università di Firenze, AOU Careggi, Firenze., Pilerci S; SOD Ematologia, Università di Firenze, AOU Careggi, Firenze., Pancani F; SOD Ematologia, Università di Firenze, AOU Careggi, Firenze, Italy; Centro Ricerca e Innovazione Malattie Mieloproliferative (CRIMM), AOU Careggi, Firenze., Signori L; SOD Ematologia, Università di Firenze, AOU Careggi, Firenze, Italy; Centro Ricerca e Innovazione Malattie Mieloproliferative (CRIMM), AOU Careggi, Firenze., Tarantino D; SOD Ematologia, Università di Firenze, AOU Careggi, Firenze, Italy; Centro Ricerca e Innovazione Malattie Mieloproliferative (CRIMM), AOU Careggi, Firenze., Maccari C; SOD Ematologia, Università di Firenze, AOU Careggi, Firenze, Italy; Centro Ricerca e Innovazione Malattie Mieloproliferative (CRIMM), AOU Careggi, Firenze., Paradiso V; SOD Ematologia, Università di Firenze, AOU Careggi, Firenze., Annunziato F; Centro Diagnostico di Citofluorimetria e Immunoterapia, AOU Careggi, Firenze., Guglielmelli P; SOD Ematologia, Università di Firenze, AOU Careggi, Firenze, Italy; Centro Ricerca e Innovazione Malattie Mieloproliferative (CRIMM), AOU Careggi, Firenze., Vannucchi AM; SOD Ematologia, Università di Firenze, AOU Careggi, Firenze, Italy; Centro Ricerca e Innovazione Malattie Mieloproliferative (CRIMM), AOU Careggi, Firenze. |
| Abstrakt: |
Measurable residual disease (MRD) is a powerful predictor of outcome in acute myeloid leukemia. In the early phases of treatment, MRD refines initial disease risk stratification and is used for the allocation to allogeneic transplant. Despite its well-established role, a relatively high fraction of patients eventually relapses albeit achieving MRDneg status. The aim of this work was to assess specifically the influence of baseline features and treatment intensity on the predictive value of an MRDneg status, particularly focusing on MRD2, measured after two consecutive chemotherapy cycles. Among baseline features, younger MRD2neg patients (<55 years) had a significantly longer disease-free survival (median not reached) compared to their older counterparts (median 25.0 months, P=0.013, hazard ratio=2.08). Treatment intensity, specifically the delivery of a high dose of cytarabine in induction or first consolidation, apparently had a pejorative effect on the outcome of MRD2neg patients compared to standard dose (P=0.048, hazard ratio=1.80), a finding also confirmed by the analysis of data extracted from the literature. The combination of age and treatment intensity allowed us to identify categories of patients, among those who reached a MRD2neg status, characterized by significantly different disease-free survival rate. Our data showed that variables such as age and intensity of treatment administered can influence the predictive value of MRD in patients with acute myeloid leukemia. In addition to underscoring the need for further improvement of MRD analysis, these findings call for a reasoned application of MRD data, as currently available, to modulate consolidation therapy on adequately estimated relapse rates. |
